<![CDATA[Merck and Daiichi withdraw their small-cell lung cancer drug bid after FDA signals Phase 2 data fell short of accelerated approval requirements]]>

<![CDATA[Merck and Daiichi withdraw their small-cell lung cancer drug bid after FDA signals Phase 2 data fell short of accelerated approval requirements]]>Merck and Daiichi withdraw their small-cell lung cancer drug bid after FDA signals Phase 2 data fell short of accelerated approval requirements

https://www.medicaldaily.com/merck-daiichi-ifinatamab-deruxtecan-sclc-application-withdrawn-479280

#wellness #cancer #medicine

]]>https://postcall.pub/topic/69bf766e-56fd-4feb-a9a0-cae37317a04c/merck-and-daiichi-withdraw-their-small-cell-lung-cancer-drug-bid-after-fda-signals-phase-2-data-fell-short-of-accelerated-approval-requirementsRSS for NodeThu, 08 Oct 2026 23:12:44 GMTWed, 30 Sep 2026 09:37:03 GMT60